The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in glioblastoma

BACKGROUND: Targeted approaches for inhibiting epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases (RTKs) in glioblastoma (GBM) have led to therapeutic resistance and little clinical benefit, raising the need for the development of alternative strategies. Endogenous LRIG1 (Le...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Adv
Autors principals: Neirinckx, Virginie, Hau, Ann-Christin, Schuster, Anne, Fritah, Sabrina, Tiemann, Katja, Klein, Eliane, Nazarov, Petr V, Matagne, André, Szpakowska, Martyna, Meyrath, Max, Chevigné, Andy, Schmidt, Mirko H H, Niclou, Simone P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Basic and Translational Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212925/
https://ncbi.nlm.nih.gov/pubmed/32642659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz024
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars